
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio is a promising investment opportunity as they have a strong and comprehensive drug development pipeline, including a potential multi-billion dollar revenue generator in tinlarebant for the treatment of degenerative retinal diseases like GA and STGD1. With a comfortable cash position and key commercialization preparations underway, they are well poised for success with a potential FDA approval in 2026 for tinlarebant as the first ever FDA-approved therapy for STGD1. The completion of their rolling NDA submission in 2Q26 highlights their commitment to bringing this important treatment to market.
Bears say
Belite Bio is a clinical stage biopharmaceutical company with a drug development pipeline that includes tinlarebant for the treatment of degenerative retinal diseases and LBS-009 for metabolic diseases. While tinlarebant has a potential multi-billion dollar market opportunity in both Stargardt disease and geographic atrophy associated with dry age-related macular degeneration, there are risks including potential failure in clinical trials and failure to achieve commercial success. The company's current valuation is based on a discounted cash flow analysis and assigned probabilities of approval for their drug candidates. Management plans to conduct an interim analysis in late 2026, and the company may use safety data from the Phase 3 PHOENIX trial to support a potential NDA for Stargardt disease.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares